Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-02-12Clinical Trial Update: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]
Pfizer-sponsored Phase 1/2 trial evaluating CPG 7909 in patients with cutaneous T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2008-10-24Clinical Trial Update: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study [Phase 1, Phase 2]
A prospective Phase 1/2 study evaluating the topical retinoid tazarotene 0.1% cream for Cutaneous T-Cell Lymphoma. The document provides tri…
-
FDA approval · 2008-07-22FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Zolinza (vorinostat) by Merck Sharp & Dohme LLC to update/expand its labeling.
-
CLINICAL_TRIALS trial_result · 2008-03-05Clinical Trial Update: Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients [Phase 4]
Phase 4 clinical trial update of ONTAK (denileukin diftitox) in patients with previously treated cutaneous T-cell lymphoma, including Mycosi…
-
CLINICAL_TRIALS trial_result · 2008-03-05Clinical Trial Update: Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients [Phase 4]
A Phase 4 clinical trial of ONTAK (denileukin diftitox) in cutaneous T-cell lymphoma patients (including mycosis fungoides and Sézary syndro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2008-03-05Clinical Trial Update: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) [Phase 4]
Phase 4 clinical trial update for ONTAK (denileukin diftitox) in Cutaneous T-Cell Lymphoma; the study status is completed.
-
CLINICAL_TRIALS trial_result · 2008-03-04Clinical Trial Update: Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac [Phase 1]
This is a completed Phase 1 trial evaluating a yttrium-90 radiolabeled anti-Tac antibody in patients with cutaneous T-cell lymphoma and adul…
-
FDA approval · 2006-10-06FDA Approved: ZOLINZA — Original Application (Merck Sharp & Dohme LLC)
The FDA approved Zolinza (vorinostat) under original NDA for cutaneous T-cell lymphoma, marking the first approval of this histone deacetyla…